9 - 11 Nov.

Financial Times Global Pharmaceutical & Biotechnology Conference

Transforming the pharma business for growth

Monday, 10:30 a.m.  GMT

This industry-leading conference brings together the world’s biggest pharma companies and other major organizations across the life sciences and health care value chain to discuss the challenges and opportunities presented by the pandemic and prepare the ecosystem for innovation to thrive in the future.

Register Now*


The life sciences sector is rapidly shifting gears to address the pandemic and offers opportunities to bring innovation to the forefront and resolve these monumental challenges. At the same time, the pharma sector continues to address important issues such as drug discovery, pipeline growth, genomics, manufacturing and supply chains, and business models.

As the industry looks to invest in a “better normal”, it is imperative to bring a fresh perspective on the critical issues impacting the pharma and biotech companies. Join Deloitte at the FT Global Pharmaceutical & Biotechnology Conference 2020 as we bring together leaders from across the industry to discuss these trends and create a successful life sciences ecosystem, respond to COVID-19, and prepare for the future.    

Deloitte is pleased to offer you a free complimentary registration to this year’s conference.

Register now*

Key issues to be addressed at the conference:

  • Reshaping the Pharma Pipeline for Growth
  • Realizing the Value and ROI of Real-World Evidence (RWE) / Real-World Data (RWD)
  • The Power of Genomics
  • The Changing Power Structure of the Industry - How is Pharma Innovation Model Evolving?
  • How Technology is Transforming R&D
  • Manufacturing- and Supply Chain - The New Competitive Edge for Pharma
  • How do we Pay for Cures?
  • The Future of Cell and Gene Therapies


Deloitte participation sessions:

9 November 2020 | 12:20 p.m.


  • David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer, Vertex Pharmaceuticals
  • Teresa Graham, Head of Global Product Strategy, Roche Pharma
  • Daniel Mahoney, Co-Head of Healthcare, Polar Capital
  • Hanno Ronte, Partner, Deloitte

11 November 2020 | 10:40 a.m.


  • Harmony Garges, Chief Medical Officer, ViiV Healthcare
  • Anne Heatherington, Senior Vice President and Head of Data Sciences Institute (DSI), Takeda Pharmaceuticals
  • Charles Makin, Global Head, Real-World Evidence Strategy, Biogen
  • Brett Davis, Principal and General Manager, ConvergeHEALTH by Deloitte

9 November 2020 | 3:20 p.m.


  • Marianne De Backer, Head of Pharmaceuticals Business Development and Licensing, Bayer
  • Gautam Gupta, Vice President, Head of Strategy and Consulting, Pfizer
  • John Maraganore, CEO, Alnylam
  • Edwin Moses, Chairman, Achilles Therapeutics, Sensorion and LabGenius


Greg Reh, Global Life Sciences & Health Care Leader, Deloitte

9 November 2020 | 3:45 p.m.


  • Craig Kennedy, Global Head of Transformation and Supply Chain, MSD
  • Stephen Ward, Chief Manufacturing Officer, Cell and Gene Therapy Catapult
  • Diane Blumenthal, Head of Technical Operations, Spark Therapeutics
James Gregson, Partner, Deloitte

10 November 2020 | 4:05 p.m.


  • Christi Shaw, CEO, Kite
  • Greg Reh, Global Life Sciences & Health Care Leader, Deloitte
*Complimentary registration is available for senior executives in the life sciences and health care industry only and is subject to final approval by the Financial Times Live.
9 - 11 Nov. 2020 10:30 a.m. GMT
Share Share event on social
Register Now*